The combination of tumour necrosis factor-(TNF-) blocking agents and methotrexate demonstrated real therapeutic efficacy by decreasing inflammation and slowing and stopping joint destruction in 70-80% of rheumatoid arthritis (RA) patients [1] [2] [3] [4] [5] [6] . Regardless of the blocking agent prescribed, about 30% of RA patients failed to respond, but we have not yet been able to identify them before initiating treatment. Even though the pathophysiological heterogeneity of RA and the existence of subgroups of patients susceptible to respond better to one molecule rather than another have been well-demonstrated, we are still unable to predict the efficacy of one treatment or another in a given patient. In addition, use of TNF-blocking agents exposes patients to certain risks (infectious, neoplastic, allergic, etc.) that seem disproportionate, especially if the patient might not respond to one of these therapies [3, 4] . Moreover, the range of biotherapies will soon be extended, as highly promising, innovative, new agents become available (interleukin-6 receptor, cytotoxic T-lymphocyte-associated antigen 4, anti-CD20), but their respective places in therapeutic strategies have not yet been defined [7, 8] . Without markers or indexes, it will be difficult to choose-among all the available agents-the molecule that will achieve immediate efficacy and will be the best adapted to a given patient. This decision is rendered even more difficult by the fact that the therapeutic targets of the various molecules are different. Because of all these unknown risks and limiting factors, it would be highly desirable to be able to identify patients susceptible to respond-or not-to a given agent. One way to achieve this objective is to identify factors predictive of a response to therapy.
At present, the only markers that have been shown to be able to predict the response to infliximab are genetic markers identified by analysis of genetic polymorphisms. Mugnier et al. [9] examined the polymorphism of the promoter gene encoding TNF-in position À308 in 59 patients treated with infliximab. Patients with the À308 G/G genotype were better responders [disease activity score (DAS) diminution >2.29] than those expressing the A/A or A/G genotype (DAS diminution >1.24). The results of those investigations are highly promising because genetic factors predictive of response can be intimately associated with mechanisms of TNF-regulation in RA, as is the case for the polymorphism of the promoter gene coding for TNF-that induces quantitative TNF-variations. Notably, the À308 A allele is associated with higher levels of TNF-transcription/transcripts than the G allele [9] .
Nevertheless, other mechanisms are also probably involved because, so far, genetic polymorphism could not explain the common clinical observation of a patient responding to one anti-TNF-agent but not necessarily others [10, 11] . In addition, those studies on polymorphism provided information concerning the efficacy of the therapeutic class of agents (TNF-blockers) in a patient, but alone, they probably do not contribute to orienting the choice of the most effective molecule among those available. Finally, as Bridges [12] recently emphasized in an editorial in Arthritis and Rheumatism, response to treatment cannot be simplified to a single polymorphism, but rather to several, because the genes interact. Thus, the identification of responders and nonresponders to TNF-blocking agents cannot be restricted to the study of cytokine polymorphisms.
What other parameters might be pertinent for the prediction of response to a biotherapy? Knowing that TNF-blocking agents are prescribed to treat severe and progressing RA, an initial approach is to measure the markers associated with RA severity: erythrocyte sedimentation rate (ESR)/1 st h, C-reactive protein (CRP), rheumatoid factors (RF), antibodies to cyclic citrullinated peptide (anti-CCP) and HLA-DRB1 Ã 04 and 01 [13] [14] [15] [16] . In addition, based on our knowledge of the pathogenic mechanisms implicated in RA, a certain number of potentially informative markers can be deduced. First and foremost, hyperplasia of synovial tissue, a real pseudotumoural process, will engender osteocartilaginous destruction, predominantly caused by metalloproteinase (MMP) 1 and MMP3, whose actions are contained by their respective tissue inhibitors (TIMP1 and TIMP2) and cartilage oligomeric matrix protein (COMP) [17] . Some markers reflect the hyper-resorption of bone, like the collagen type 1-crosslinking molecules [pyridinoline (PYD) and deoxypyridinoline (DPYD)], but also the receptor activator of nuclear factor-B-receptor activator of nuclear factor-B ligand (RANK-RANKL) system and osteoprotegerin (OPG) [18, 19] . Moreover, the antioxidants-vitamins A and E, and selenium-counterbalance the free radicals that reflect inflammation. Several studies showed negative correlations between RA severity and serum antioxidant concentrations [20] [21] [22] [23] . Finally, recent data plead in favour of a major role for B-lymphocytes in the pathogenesis of RA, as attested by the increasing number of autoantibodies (autoAb) found in this pathology. These biological parameters, combined in various associations, might be able to predict the response to TNF-blocking agents, especially because some of them are regulated by TNF-.
The primary objective of this prospective, longitudinal study on RA patients naı¨ve to all biotherapies was the identification of markers able to predict the response to infliximab given in combination with methotrexate or leflunomide. To identify such indicators in patients whose RA was resistant to diseasemodifying anti-rheumatic drugs (DMARDs), soluble markers (proteases, autoAb, antioxidants) known to have a prognostic or pathophysiological value were measured in serum before starting infliximab. In this exploratory analysis, two biostatistical methods-univariate analysis and microarray hierarchical clusteringwere applied to attempt to identify potential biochemical, immunological and bone markers as predictors of RA patients' responses to infliximab combined with methotrexate or leflunomide.
Materials and methods

Patients
A total of 76 patients with RA satisfying the American College of Rheumatology (ACR) criteria and followed in our Rheumatology Department were included in this prospective, longitudinal study. These patients had active RA refractory to methotrexate and/or leflunomide that necessitated combining infliximab (Remicade TM , Schering Plough, Levallois-Perret, France) to their treatment regimen. Their disease failed to respond to DMARD (methotrexate had to have been tried unless contraindicated); RA was active with at least three of the following five criteria: !3 synovia affected, !6 painful joints, duration of morning stiffness !45 min, ESR >22 mm/1 st h, CRP >20 mg/l; DMARD therapy with methotrexate or leflunomide was used, regardless of the dose prescribed. The sole criterion of non-inclusion was contraindication of infliximab administration. Patients included gave their written consent to participate in this protocol that had been approved by the Upper Normandy Ethics Committee (protocol 2002/061 HP).
Infliximab infusions
Infliximab was administered intravenously by slow perfusion at the manufacturer's recommended dose of 3 mg/kg throughout the study at weeks 0, 2, 6 and 14, and then every 8 weeks. Treatment efficacy was evaluated with response criteria established by the European League Against Rheumatism (EULAR) based on DAS28 [24] .
Clinical parameters
At the inclusion visit, the following information was collected: sex, age, RA duration, RA history, DMARDs prescribed and their doses, concomitant regimens (corticosteroids and dose), night time awakenings or not, duration of morning stiffness, pain evaluation using a visual analogue scale (VAS) ranging from 0 to 100 mm, the patient's evaluation of disease activity with a VAS, number of painful joints, number of joints with synovitis and the French version of the Health assessment questionnaire (HAQ) [25] .
Then, disease activity was re-evaluated just before each infliximab administration by collection of the following information: duration of morning stiffness, pain evaluation using the VAS, the patient's evaluation of disease activity with the VAS, number of painful joints, number of joints with synovitis, ESR, CRP and HAQ.
Biological parameters tested
Before the first infusion, a serum library was constituted for all the patients to determine various biological parameters (immunological, biochemical, osteocartilaginous) with the aim of identifying markers predictive of the response to treatment. These sera were stored at À308C until evaluation. The IgM-class RFs were detected using latex agglutination and Waaler-Rose tests. The other immunological markers were measured using enzyme-linked immunosorbent assays (ELISA) devised in the immunology laboratory, RF isotypes IgG, IgA and IgM; autoAb directed against calpastatin domain I (ACAST-DI) and its 27-mer C-terminal fragment (ACAST-C27), glucose-6-phosphate isomerase (G6PI)) or with a commercially available anti-CCP ELISA kit (Bio Avance, Emerainville, France) according to the manufacturer's instructions [26] [27] [28] [29] . Anti-perinuclear factor (APF) and anti-keratin antibodies (AKA) were detected by direct immunofluorescence labelling [26] . AutoAb to -enolase were identified using an immunoblotting technique, with human placenta as the antigen source. Sera recognizing a 50 kDa polypeptide band were considered to have anti--enolase activity [30] . The CRP concentration was determined nephelometrically. MMP1 and MMP3 and their respective inhibitors, TIMP1 and TIMP2, were measured with ELISA-type immunoenzymatic assays (Human Biotrak TM Assay, Amersham Biosciences, Buckinghamshire, UK). Vitamins A and E and selenium concentrations were measured by high-performance liquid chromatography (Dionex, Voisins le Bretonneux, France) after vitamin/selenium extraction from serum with reagent kits (Chromosystem, Munich, Germany). The osteoarticular markers indicative of bone/cartilage destruction were measured using ELISA kits according to the manufacturer's instructions: for PYD and DPYS (respectively, Metra Serum PYD EIA kit and Metra Total DPD EIA kit Serum; Quidel, San Diego, CA, USA), for RANKL and OPG (sRANKL and Osteoprotegerin, Biomedica, Wien, Germany) and for COMP (COMP Õ ELISA, AnaMar Medical, Uppsala, Sweden).
Statistical analyses
All the clinical and biological parameters collected before the onset of infliximab were analysed, except those used to evaluate treatment efficacy. Data analysis was conducted according to the criteria established by EULAR that defined three levels of response: good, moderate and non-responders. Each patient's response was determined using the DAS 28 calculated just before the fourth infliximab infusion. Because of the small number of good responders among these patients, moderate and good responders were pooled and called the responders. The predictive ability of the pretherapeutic parameters for the principal judgement criterion (dichotomous variable: responder or nonresponder) was subjected to univariate test analysis. The search for a relationship between initial criteria comprising dichotomous (presence or absence of autoAb, . . .) and continuous variables (CRP median, autoAb titre, . . .) and the judgement criterion was conducted using Fisher's exact test or the Mann-Whitney U-test. An association was considered statistically significant when P < 0.05. For quantitative variables, analysis of variance and Kruskal-Wallis rank-sum tests were applied to compare medians. When the global test was significant, multiple comparisons were conducted between responders and non-responders (KruskalWallis multiple-comparison Z-value test), with P < 0.05 retained as significant.
The power of this study was calculated and ranged from 5 to 20% for the different tests used for each qualitative or quantitative variable. To obtain a difference of 10% between responders and non-responders, which is that observed in the present study, 500 patients are required to have a power of 80% with 5% -risk (two-tailed) of a qualitative variable, when the percentage of responders is 60-70%.
Hierarchical clustering analysis of data
Microarray hierarchical clustering is a method taken from the tools used for transcriptome analysis. It allows simultaneous comparison of one patient's biological profile including all the parameters considered to the individual profiles of the other patients. Hierarchical clustering regroups the patients according to the similarities of their biological profiles and identifies the combinations of variables classifying the patients. For each patient and each biological variable, the value determined for one patient is normalized as a function of the median of all the values obtained from this population. Microarray data analysis was then conducted using TIGR Multiple Experiment Viewer (TMEV) http://www.tigr.org/software/tm4/mev.html with the hierarchical clustering function [31] [32] [33] .
Results
Patient characteristics
Just prior to the first infliximab infusion, the 76 patients (62 women and 14 men) had a mean AE S.D. age of 53.8 AE 12.4 yrs, with RA progressing for 10.5 AE 8.6 yrs; all of them had a DAS28 > 3.2. Their clinical and biological characteristics are summarized in Table 1 . Their clinical and biological characteristics are summarized in Table 1 . Responders and nonresponders did not differ significantly for the number of previous DMARDs taken.
Evaluation of the response to infliximab
The judgement criterion applied to assess the response to infliximab was the DAS28 value obtained just before the fourth infusion. However, to limit the errors of judgement of therapeutic efficacy based on that single DAS28 evaluation, we also verified that the mean of three DAS28 evaluations (made just before the third, fourth and fifth infusions) classified the patients similarly according to their response levels (data not shown). The percentages of responders were comparable (McNemar test ¼ 0.18) and concordant (kappa test: 0.6 < P < 0.8), regardless of the way in which the response was evaluated (one or three evaluations). In addition, Fisher's test was highly significant (n ¼ 10 À6 ), thereby indicating a strong statistical association between the two types of evaluations (i.e. the mean of one or three DAS). Therefore, in accordance with EULAR recommendations, the evaluation at 14 weeks of treatment was finally retained for this prospective study.
Good, moderate and non-responders represented 7.8 (n ¼ 6), 53.9 (n ¼ 41) and 38.1% (n ¼ 29), respectively. Because of the small number of good responders, good and moderate responders were pooled (n ¼ 47, 61.8%) for analysis and this group of responders was compared with non-responders. Infliximab and methotrexate led to significant improvement of all the clinical and biological parameters (morning stiffness, VAS for pain, VAS for disease activity, number of painful joints, number of joints with synovitis, ESR, CRP, DAS28 and HAQ) for the responders, while significant improvement for the non-responders was limited to the number of joints with synovitis, DAS28 and HAQ. In the group of responders, each variable improved significantly under treatment. Moreover, the extent of improvement of all clinical and biological parameters obtained during therapy differed significantly between responders and non-responders.
Univariate analyses
As reported in Table 2 , univariate analysis of dichotomous variables did not identify any parameter as being predictive of the response to infliximab. Only the DMARD prescribed (methotrexate vs leflunomide) tended to differ significantly between responders and non-responders, with 82.6% of the responders as opposed to 62.1% of non-responders treated with methotrexate. Patients taking methotrexate had a better response on infliximab than those prescribed leflunomide (P ¼ 0.059).
As reported in Table 3 , univariate analysis of quantitative variables failed to identify markers predictive of the response to infliximab. The medians of all these variables did not differ significantly between responders and non-responders (Table 3) .
Hierarchical clustering analysis
Analysis of biological data by microarray hierarchical clustering failed to elucidate characteristic profiles of responders and nonresponders, and regroup them into distinct subgroups (Fig. 1) .
Discussion
The main objective of this exploratory study was to identify clinical and/or biological markers able to predict a good or poor response to infliximab in patients with active RA refractory to conventional DMARDs (methotrexate and leflunomide). This investigation concerned 76 patients with longstanding RA (10.5 AE 8.5 yrs), 80.2% of whom were RF-positive. They received infliximab infusions (3 mg/kg) according to the standard therapeutic schedule. Just prior to the first infusion, blood was drawn from all patients to determine serum levels of biological markers implicated in the pathophysiology of RA and/or associated with its severity.
The judgement criterion for therapeutic efficacy in this prospective study was, as recommended by EULAR, based on DAS28 before starting infliximab and 14 weeks later just prior to the fourth infusion at the end of the 8-week interval, when the majority of patients generally reported the reappearance of symptoms [24] . The patients were classified as responders or non-responders, because these classes take into consideration the DAS28-based improvement (compared with the patient's initial status) and RA activity at the time of evaluation, unlike ACR criteria that only consider improvement.
The percentage of non-responders to infliximab (38.2%) observed in our study is close to that generally reported in phase III/IV therapeutic trials (30-40%) [1] [2] [3] [4] . Using the DAS44 as the judgement criterion calculated at the sixth infusion, Sidiropoulos et al. [34] obtained respective good, moderate and non-responder rates of 18.8, 37.5 and 43.7% of 68 patients, compared with our respective rates of 6.5, 61.8 and 31.5%. This discordance probably reflects the difference between using DAS44 and 28 as the judgement criterion, and the time of evaluation at the sixth or fourth infusions. In addition, in their study, the methotrexate and/or infliximab dose was adapted to the response at the fourth infusion.
The selection of serum parameters that could potentially be markers predictive of the response to infliximab was based on pathophysiological and clinical arguments. The biological parameters retained can be associated with the progression of bone/ cartilage destruction (RF and isotypes) and/or implicated in RA pathophysiology. These latter include: autoAb to CCP, G6PI, calpastatin, etc.; the bone/cartilage-destruction by products COMP, sRANKL, OPG, . . .; indicators of inflammation, such as MMPs, their inhibitors (TIMPs), antioxidants and CRP. Moreover, many of these markers are already known to be direct targets of TNF-blocking agents because their serum Values reported are the medians for each group; responders comprise good and moderate responders. Medians were compared using the MannWhitney U-test or Wilcoxon's rank-sum test. ACAST-C27, autoantibodies recognizing the calpastatin 27 C-terminal fragment; ACAST-DI, autoantibodies recognizing calpastatin domain I; anti-CCP, anti-cyclic citrullinated peptide antibodies; anti-G6PI, anti-glucose-6-phosphate isomerase antibodies; AKA, anti-keratin antibodies; APF, antiperinuclear factor; AU, arbitrary units; CRP, C-reactive protein; DPYD, deoxypyridinoline; MMP1/3, metalloproteinase 1 or 3; OPG, osteoprotegerin; PYD, pyridinoline; RF-IgG/IgA/IgM, rheumatoid factor isotype IgG, IgA or IgM; sRANKL, soluble receptor activator of nuclear factor-B ligand; TIMP1/2, tissue inhibitor of metalloproteinase 1 or 2 and VAS, visual analogue score. The values reported are the percentages of patients with positive rates for the marker evaluated. These percentages correspond to the sensitivity of each test for this patient population, they were compared using Fisher's exact test.
ACAST-C27, autoantibodies recognizing the calpastatin 27 C-terminal fragment; ACAST-DI: autoantibodies recognizing calpastatin domain I; anti-CCP, anti-cyclic citrullinated peptide antibodies; anti-G6PI, antiglucose-6-phosphate isomerase antibodies; AKA, anti-keratin antibodies; APF, anti-perinuclear factor; DPYD, deoxypyridinoline; MTX, methotrexate; OPG, osteoprotegerin; PYD, pyridinoline; RF-IgG/IgA/IgM, rheumatoid factor isotype IgG, IgA or IgM and sRANKL, soluble receptor activator of nuclear factor-B ligand.
concentrations decline during treatment, as is the case for OPG, sRANKL, COMP, MMP1, MMP3, MMP9 and their inhibitors TIMP1 and TIMP2, nitric oxide (known to destroy joints) and RF; but not always anti-CCP antibodies [35] [36] [37] [38] [39] [40] [41] . These biological parameters were measured in serum taken prior to infliximab administration in an attempt to identify markers predictive of the response to this TNF-blocking agent.
For this group of patients with active RA, no studied parameter was able to predict a good or poor response to infliximab. In this study, multivariate analysis was not performed because of the lack of statistically different soluble markers between responders and non-responders with the univariate analysis. Moreover, P-values between responders and non-responders in analysis univariate were much dismissed of 0.05. Although the difference was not significant, the only clinical factor susceptible to distinguish responders and non-responders was the associated DMARD, methotrexate or leflunomide. The percentages indicate a better response under methotrexate. Even though associating infliximab with methotrexate seems to have better efficacy than with leflunomide, methotrexate cannot be considered a marker predictive of a good response, especially because 54.2% of the non-responders were taking methotrexate. Furthermore, 75% of our RA patients were taking methotrexate vs 25% on leflunomide. Unlike conventional statistical methods, microarray analysis with hierarchical clustering is able to compare one patient's profile with those of all the others included in the study. The analysis of pre-infliximab serum parameters using the biological profiles of each patient also failed to distinguish between responders and non-responders. Therefore, parameters shown to be predictive of severity or implicated in the pathophysiology of RA do not appear to be relevant for the identification of markers predictive of the therapeutic response.
The results of this study are completely compatible with those of the rare reported investigations in this field. The ATTRACT (Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy) study also failed to identify a clinical parameter able to predict the response to infliximab, among the following: disease duration, age, presence of rheumatoid nodules, DAS28 and the presence of erosions on standard radiographs [42] . In addition, among 20 RA patients treated with infliximab for 1 yr (13 responders and 7 non-responders) Hrycaj et al. [43] tried to identify markers predictive of the response by measuring the following before and 2 weeks after the onset of treatment: ESR, RF-IgM, CRP, C3 and C4 fractions of complement, 1 -acid glycoprotein, 1 anti-trypsin, serum concentrations of interleukins 4, 6 and 13, TNF-types I and II. The pre-treatment determinations were not predictive of response. Their search for a statistical relationship between the response and the difference between pre-treatment and 2 weeks post-infusion 1 was also unsuccessful [43] .
Wolbink et al. [44] observed a statistical relationship between the clinical response and two biological parameters, the serum infliximab concentration and the CRP level, measured in 105 patients. The DAS28 was calculated before each infusion as in our study and patients were classified in to three groups according to their initial serum CRP concentration (A: 0-10 mg/l; B: 11-39 mg/l; C: 40-120 mg/l). The serum infliximab concentration at 14 weeks was higher in responders than non-responders, indicating better neutralization of TNF-in responders, and it was higher in patients with low CRP concentrations before starting treatment (group A). These patients also had improved DAS28 when the infusions were given at 8-week intervals. The authors concluded that serum infliximab and CRP concentrations determined the capacity of infliximab to neutralize TNF-. Higher CRP levels justified shorter intervals between infusions or higher doses of infliximab. In contrast to their findings, the median serum CRP concentration did not differ significantly between our responders and non-responders. Our conclusions should be viewed with caution. Indeed, as we observed in our study, all response levels can be seen, which means that the response to TNF-blocking agents is not binary. To identify markers predictive of the response, it might have been necessary to compare only good vs non-responders, which we could not do because of the small number of good responders. The relatively small sample size is explained by the characteristics of this prospective study. First, the retained population is consistent with the recruitment capacity of the Rheumatology Department of the Rouen University Hospital during this well-defined period (January 2002-October 2003) and the number of patients satisfying the disease criteria given earlier. Second, this inclusion strategy obtained a homogeneous population enabling comparison of potential differences. Indeed, patients receiving infliximab monotherapy, intolerant of methotrexate or leflunomide, or prescribed azathioprine were excluded from this study to achieve such a homogeneous population. Moreover, at the end of 2003, etanercept had just become available in France and competed with infliximab. To offset this difficulty in subsequent studies, more patients must be included to have sufficiently large responder and non-responder groups for comparisons.
In addition, the TNF-blocking agent studied probably influenced the judgement criterion. The DAS28 calculated at 14 weeks of treatment is probably more reliable for biotherapies regularly administered subcutaneously (etanercept, adalimumab, interleukin-1 receptor antagonist) than infliximab given intravenously every 6 or 8 weeks, thereby highlighting the potential contribution of evaluation during the between-infusion interval that was not programmed in this study. Managing patients in a hospital-private practice network by means of file sharing, for example, can easily rectify this weakness. Furthermore, infliximab was only evaluated at 3 mg/kg, while it is well-established that a substantial percentage of patients fail to respond to this dosage. Therefore, true infliximab (INF) non-responders would be RA patients who have failed to respond to escalating dosages of infliximab. Several of the non-responders might have been classified as responders if higher doses of INF had been given. This is certainly a limitation of this study but we respected recommendations of the French authorities. Finally, the criterion of DAS28 response after 1 yr of treatment was not retained because some patients were withdrawn from the study due to sideeffects or treatment failures and the dose infused or intervals between infusions were adapted to the response after the fifth infusion. As a consequence, the methodology applied here (nonrandomization of DMARD, absence of intermediate evaluation, number of patients) probably contributed to skewing the analysis of the data preventing the identifications of markers predictive of the response. In addition, radiographs of the hands and feet, and their assessment with the Sharp score modified by van der Heijde, were not analysed as criteria of a structural response and/or a potential predictive marker. Indeed, patients with high Sharp scores might respond better to infliximab than patients with low scores. Pertinently, the ASPIRE (active controlled study of patients receiving infliximab for the treatment of RA of early onset) study patients who responded best to the methotrexateinflixmab combination had more severe structural involvement at inclusion [45] . In our study, the Sharp score was not included into the analysis because our objective was to identify factor(s) predicting the response to infliximab and methotrexate or leflunomide that might easily be used in routine practice. Other parameters could have been considered: pro-angiogenic molecules, like vascular endothelial growth factor (VEGF), which are being evaluated in another ongoing trial. Measurement of serum infliximab concentrations has not yet become a routine laboratory test. Finally, because of their high cost, genetic polymorphism analyses could not be carried out for all the patients included in this study. Although genetic markers (genetic polymorphisms) seem to coincide better with an approach detecting markers predictive of a good therapeutic response, the reasons listed above do not enable us to formally exclude the relevance of analysing soluble molecules, especially because the TNF-blockers have an impact on some of them.
Indeed, analysis of the polymorphism of certain genes seems promising but the identification of responders and non-responders to TNF-blocking agents cannot be restricted to the study of cytokine polymorphisms, even though these molecules are currently thought to play major roles in RA pathophysiology. Hence, other approaches are needed to identify markers predictive of the response. Examination of gene-expression levels is one possible strategy to identify target genes or candidates for polymorphism studies, but also genetic markers that a priori have no apparent association with the pathophysiology and/or mode of action of the molecule tested. Transcriptomic and proteomic approaches also represent tools that could be used to identify these sought after markers. In the long-term, these bioinformatics tools should enable the construction of algorithms integrating all the genetic, transcriptomic and proteomic data to identify a combination of markers able to predict the response to a molecule and thereby improve treatment of RA.
Conclusion
The principal objective of our study on 76 patients with severe and longstanding RA was to identify marker(s) predictive of the response to infliximab combined with methotrexate or leflunomide. The clinical and biological parameters routinely used, the parameters associated with RA severity and some biological parameters implicated in RA pathophysiology are not able to predict the response to infliximab. In this study, the too small sample size and lack of good responders (a consequence of the former) probably contributed to limiting the detection of potential markers of responsiveness to infliximab. This approach was used as a preliminary and original exploratory analysis and, based on its results, we cannot yet preclude the existence of predictive markers. Other studies including more patients are required to conclude as to the contribution of soluble markers in this context.
